共 86 条
[1]
Kim SJ(2013)Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer Cancer Sci 104 116-23
[2]
Kim YJ(2012)Adjuvant therapy for gastric cancer: revisiting the past to clarify the future J Clin Oncol 30 2297-9
[3]
Kim JH(2006)Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 11-20
[4]
Park Do J(2007)Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810-20
[5]
Kim HH(2012)Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial Lancet (London, England) 379 315-21
[6]
Lee JS(2001)Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 725-30
[7]
Brooks GA(1998)Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715-20
[8]
Enzinger PC(2011)Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies OncoTargets and therapy. 4 193-201
[9]
Fuchs CS(2013)Adjuvant chemotherapy for elderly patients with gastric cancer after D2 gastrectomy PloS one 8 e53149-9
[10]
Cunningham D(2010)7th edition of the AJCC cancer staging manual: stomach Ann Surg Oncol 17 3077-40